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Background: Histone lysine methylation has a pivotal role in regulating the chromatin. Histone modifiers, including
histone methyl transferases (HMTases), have clear roles in human carcinogenesis but the extent of their functions
and regulation are not well understood. The NSD family of HMTases comprised of three members (NSD1, NSD2/
MMSET/WHSC1, and NSD3/WHSC1L) are oncogenes aberrantly expressed in several cancers, suggesting their
potential to serve as novel therapeutic targets. However, the substrate specificity of the NSDs and the molecular
mechanism of histones H3 and H4 recognition and methylation have not yet been established.
Results: Herein, we investigated the in vitro mechanisms of histones H3 and H4 recognition and modifications by
the catalytic domain of NSD family members. In this study, we quantified in vitro mono-, di- and tri- methylations
on H3K4, H3K9, H3K27, H3K36, H3K79, and H4K20 by the carboxyl terminal domain (CTD) of NSD1, NSD2 and NSD3,
using histone as substrate. Next, we used a molecular modelling approach and docked 6-mer peptides H3K4 a.a. 1-7;
H3K9 a.a. 5-11; H3K27 a.a. 23-29; H3K36 a.a. 32-38; H3K79 a.a. 75-81; H4K20 a.a. 16-22 with the catalytic domain of the
NSDs to provide insight into lysine-marks recognition and methylation on histones H3 and H4.
Conclusions: Our data highlight the versatility of NSD1, NSD2, and NSD3 for recognizing and methylating several
histone lysine marks on histones H3 and H4. Our work provides a basis to design selective and specific NSDs
inhibitors. We discuss the relevance of our findings for the development of NSD inhibitors amenable for novel
chemotherapies.
Keywords: Epigenetic therapy of cancer, Histone lysine methyltransferase, NSD1, NSD2/MMSET/WHSC1, NSD3/
WHSC1L, HMTase inhibitorsBackground
Covalent histone modifications are key in chromatin
regulatory mechanisms. One such histone modification,
lysine methylation, can have both activating and repres-
sive functions on transcriptional events. Histone lysine
methyltransferases (HMTases) are transcriptional co-
regulators that target specific lysines on histones H3 and
H4, and can transfer up to three methyl groups (Kme1,
Kme2, and Kme3) [1]. However, the molecular mecha-
nisms of histone mark recognition remain unclear [2-6].
Epigenetic marks on H3K4, H3K9, H3K27, H3K36,
H3K79, and H4K20 have been reported to play primary
roles in regulating the chromatin and contribute to the
histone code that is still obscure [7]. H3K4, H3K36 and* Correspondence: eric.diluccio@gmail.com
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unless otherwise stated.H3K79 methylation are associated with a locally relaxed
chromatin and transcriptionally active genes, whereas
methylation of H3K9, H3K27 and H4K20 are repressors
and hallmarks of condensed chromatin at silent loci.
Dysfunctions in the regulation of histone methylation are
linked to an increasing number of pathological conditions.
The nuclear receptor-binding SET domain (NSD) fam-
ily, a part of the HMTase KMT3 family, is composed of
three HMTases: NSD1, NSD2/MMSET/WHSC1, and
NSD3/WHSC1L1 (hereafter NSD1, NSD2 and NSD3)
[8]. The NSD proteins are oncogenes highly expressed
in numerous pathological conditions and are considered
attractive novel therapeutic targets in cancers [2,9-20].
The amplification of NSD1 has been reported in mul-
tiple myeloma, lung cancer, neuroblastoma and glioblast-
oma. The amplification of either NSD1 or NSD2 triggers
cellular transformation [21-28]. NSD2 is associated with
tumor aggressiveness or prognosis in most types ofl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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loma and is overexpressed in at least 15 different cancers
[9,10,17,18,20,21,25,29-33]. Increased NSD2 activity is
also reported during tumor proliferation in glioblastoma
and myeloma [34], resulting in aberrantly high global
levels of H3K36me2 [18]. NSD3 is amplified in primary
breast carcinoma, bladder cancer, lung cancer, and liver
cancer [12,16,25,35]. Abnormal fusion proteins contain-
ing NSD family members, including NSD1-NUP98 and
NSD3-NUP98 fusions, increase H3K36 methylation,
leading to acute myeloid leukemia [24-28].
Although NSD proteins are instrumental in the devel-
opment of numerous cancers, their mechanisms of ac-
tion in carcinogenesis are still unclear. In particular, the
substrate specificity of the NSD members remains unset-
tled and conflicting data have been reported [17,20].
NSD1 has H3K36-specific mono- and di-methylation
activities but methylation on H4K20 by NSD1 has also
been reported [3,23,27,36]. NSD2 activity performs
H3K36-specific mono- and di-methylation on chroma-
tin, but di-methylation activity for H4K20 at DNA
double-strand breaks has also been reported [17,20]. A
significant increase in H3K36me3 by NSD2 at promoter
regions has also recently been demonstrated [4], but po-
tentially ruled-out in another study [20]. In addition,
NSD2 has been shown to methylate H3K4, H3K27, and
H4K44 [5,6,36-38]. Discrepancies regarding NSD3
methylation activities on H3K4, H3K27, and H3K36
have also been reported [6,24,39-41]. Complicating the
mechanisms further, both NSD1 and NSD2 have been
shown to methylate NF-κB [8,42]. Thus, no consensus
on the substrate specificity of the NSD members has
been established [17,20,36]. Multiple factors may be
responsible for these discrepancies, such as the cellular
context, the nature of the substrate (peptide, histone, or
nucleosome), the integrity of the enzymes (catalytic
domain alone versus full-length protein), and the assays
employed.Figure 1 The NSD family of HMTase. A- The schematic primary structure
domains, four PHD zinc finger domains, and a CD. The CD has HMTase activit
loop over the histone-binding site is indicated in red. B- Coomassie Blue stain
NSD2-CTD, and NSD3-CTD.Despite uncertainties regarding NSD substrates, it
appears that increased levels of H3K36 methylation con-
comitant with decreased levels of H3K27 methylation by
deregulated NSD members is a driving mechanism in
chromatin regulation [13]. Therefore, the inhibition of
NSD members by small molecules represents a valuable
therapeutic strategy in several human cancers where
elevated levels of NSD members have been reported
[2,4,5,12,14,17,18,26,32,33,43-45].
The NSD family members are large multi-domain pro-
teins with four zinc finger domains, two PWWP domains
and a catalytic SET domain (Figure 1A) [9,10,17,20]. The
SET domain is subdivided into pre-SET, SET, and post-
SET domains, all domains are required for catalytic func-
tion (Figure 1A). The function of PHD1-3 and PWWP1-2
domains of the three NSD members on chromatin re-
mains elusive. However, a recent study demonstrated the
role of the conserved PHD4 domain in localizing NSD3
on histone H3 [46]. The PHD4 domain of the NSDs may
function as a recognition module for histone-lysine marks,
helping to position the catalytic SET domain on its lysine
substrate [46]. The PHD4 domain is 36-residues down-
stream of the post-SET subdomain. Due to its immediate
vicinity to the post-SET subdomain, PHD4 may be a struc-
tural component of the catalytic SET domain. Similarly,
the PWWP2 domain is also conserved across NSD mem-
bers and 72-residues upstream of the pre-SET subdomain.
The role of this PWWP2 domain remains unclear.
Previous studies have investigated either full-length
NSD members or the catalytic SET domain alone through
various experimental approaches, resulting in discrepant
conclusions. Herein, we focus on understanding histones
H3 and H4 recognition and methylation in vitro by the
NSDs. In this study, we investigate the function of the
carboxyl terminal domain (CTD) of all three NSD mem-
bers using a consistent experimental approach, in vitro.
The NSDs-CTD contains the pre-SET, SET, post-SET, and
PHD4 domains within the catalytic core as well as aof NSD1, NSD2, and NSD3: All NSD members contain two PWWP
y and contains the pre-SET, SET, and post-SET domains. The regulatory
ing of a SDS-PAGE gel confirms the expressed recombinant NSD1-CTD,
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methylation properties of the CTD of NSD1, NSD2,
and NSD3 on H3K4, H3K9, H3K27, H3K36, H3K79,
and H4K20 in vitro. Next, we used MD simulations to
elucidate the binding of the NSD catalytic SET domain
(CD) on histone tails. Taken together, this study pro-
vides insights relevant to the design of specific and
selective NSD inhibitors.Methods
Cloning
The carboxyl terminal domains (CTD) of NSD1, NSD2,
and NSD3 genes were cloned as follows; NSD1-CTD
(1338 bp, 5325? 6663 nt; encoding 446 a.a., 1775? 2221
a.a.), NSD2-CTD (1287 bp, 2808? 4095 nt; encoding 429
a.a., 936? 1365 a.a.), and NSD3-CTD (1344 bp, 2967? 4311
nt; encoding 484 a.a., 989? 1437 a.a.) were amplified by
PCR using a human liver cDNA library (TAKARA,
Japan) as the template. The sets of forward and reverse




ACATGGAGGGGGAC-3′ and 5′- CGCCTGCTCGA
G(XhoI)TTTGCCCTCTGTGACTCTCCG-3′ for NSD
2-CTD, and 5′- CTGAACGTCGAC(SalI)GGCCTTAA
ACATGACTTGGGG-3′ and 5′- GACACCGCGGCCG
C(NotI)ATTCTTTTACTTCTTCTCCATG-3′ for NSD
3-CTD. The PCR-amplified NSD1-CTD and NSD3-
CTD fragments (with SalI and NotI restriction sites)
and the NSD2-CTD fragment (with NdeI and XhoI re-
striction sites) were inserted into the corresponding
restriction enzyme sites of the multi-cloning site of
the protein expression intein-tagging vectors pTYB2
or pTYB12 (New England Biolabs, USA). All se-
quences were verified by sequencing.
Protein expression and purification
Escherichia coli expression BL21 (DE3) strain was trans-
formed with pTYB2 or pTYB12 plasmids harbouring
NSD1-CTD, NSD2-CTD, and NSD3-CTD (NSD-CTDs).
The transformed strains were grown in LB medium
containing 100 μg/mL ampicillin and the expression of
recombinant NSD-CTDs was induced with 250 μM
isopropyl 1-thio-D-galactopyranoside (IPTG) for 4 h at
15 ?C. E. coli cells were harvested and lysed by a freeze-
thaw method and incubated in buffer A [20 mM Tris
(pH 8.5), 500 mM NaCl and 0.1 mM EDTA] containing
0.1 % Triton X-100 and 1 mM phenylmethanesulfonyl-
fluoride (PMSF) and treated with 20 cycles of sonication
on ice. The resulting cell extract containing NSD-CTD-
Intein-CBD (chitin-binding domain) fusion proteins was
loaded onto an affinity column of chitin beads and washedwith 100 column volumes of buffer A with 0.1 % Triton
X-100, followed by 20 column volumes of buffer A with-
out Triton X-100. To remove bacterial chaperones bound
to the recombinant proteins, the recombinant NSD-CTD-
bound chitin beads were washed with 10 bed volumes of
buffer A containing 10 mM adenosine triphosphate (ATP)
and 2.5 mM MgCl2. The affinity column was washed with
20 bed volumes of buffer A and NSD-CTD proteins were
cleaved off from the chitin beads by incubation in buffer A
with 50 mM 2-mercaptoethanol at 4 ?C for 64 h. After
elution in buffer A, samples were concentrated and 2-
mercaptoethanol was washed off using Amicon Ultra cen-
trifugal filters (Millipore, USA) and then used for methyl-
transferase assays. A small portion of purified NSD-CTDs
was resolved through SDS-PAGE and Coomassie staining
showed soluble and pure NSD-CTDs at approximately the
expected molecular weight of 52.9 kDa (NSD1-CTD), 49.7
kDa (NSD2-CTD) and 53.1 kDa (NSD3-CTD) (Figure 1B).
The resulting recombinant NSD-CTDs proved stable and
retained their catalytic properties for an extended period
of time when stored at −80 ?C.
Histone methyltransferase assays
Histone methyltransferase activities of NSD-CTDs on
H3K4, K9, K27, K36, K79, and H4K20 were measured
using colorimetric quantification kits (Epigentek, USA)
following the manufacturer ? s protocol. As for H3K36,
H3K79 and H4K20, the purified recombinant NSD-
CTDs (0.2 μg and 2.0 μg) were incubated with a recom-
binant histone H3 or H4 (Epigentek, USA) and a
methyl group donor (SAM) in the strip wells coated
with the specific antibodies for 60 ? 90 min at room
temperature. The specific antibodies attached to the
bottom of the strip wells captured methylated sub-
strates. As for H3K4, H3K9, and H3K27, instead of the
antibody-coated strip wells, biotinylated histone sub-
strates were used and stably captured on the strip wells
during the 60 min incubation at 37 ?C. The captured bio-
tinylated histone substrates were next incubated with a
high-affinity antibody for 60 min at room temperature
with shaking at 100 rpm. Excess of purified NSD-CTDs,
histones, SAM, and antibodies were thoroughly washed
away and the strip wells attached with antibody-bound or
biotinylated H3/H4me were incubated with the labeled
detection antibodies for 60 min at 24 ?C, swirling at 100
rpm in the dark. After thoroughly washing the wells,
the methylation level was quantified through a HRP-
conjugated secondary antibody-color development system
with an ELISA plate reader at 450 nm. The antibodies
provided by Epigentek are validated and showed no
cross-reaction between the substrates. Assays were
performed in duplicate. The results were normalized
against a control that did not contain any enzymes (NC
in Figure 2).
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The crystal structure of the catalytic domain (CD) of NSD1
(PDB: 3OOI - a.a. 1850? 2080) served as a template for
building homology models of NSD2-CD (a.a. 971? 1202)
and NSD3-CD (a.a. 1044? 1283). Multiple-sequence align-
ment was done with ClustalW V2.0.9 and 100 models were
generated using Modeler V9.5. The best model, according
to the intrinsic Modeler function, was subjected to side-
chains positioning using the SCWRL4 program. Stereo-
chemistry was checked with PROCHECK. The model was
manually inspected with COOT. The histone tail peptides
were manually built in COOT with the following residues:
H3K4 (a.a. 1? 7), H3K9 (a.a. 5? 11), H3K27 (a.a. 23? 29),
H3K36 (a.a. 32? 38), H3K79 (a.a. 75? 81), and H4K20 (a.a.
16? 22). A structural overlay between NSD1-CD (PDB:
3OOI) and the crystal structure of SET8 bound to histone
H4 peptide (PDB: 3F9Y) was used to manually place and
orientate the H3- or H4-peptide tails into the histone
binding site of NSD1-CD, NSD2-CD, and NSD3-CD usingFigure 2 HMTase activities of NSD1-CTD, NSD2-CTD, and NSD3-CTD o
NSD2-CTD, and NSD3-CTD on H3K4, K9, K27, K36, K79, and H4K20 were measu
assays were done in duplicate individual experiments and all samples were in
normalized against controls that did not contain any enzymes (NC, 0 μg). Asterthe SSM algorithm in COOT. Prior to MD calculations,
all the raw modelled histone tail peptides exhibited a simi-
lar conformation. Electrostatic charge calculations were
performed using the PDB2PQR Server (http://nbcr-222.
ucsd.edu/pdb2pqr_1.9.0/) with default settings (PARSE
forcefield) regardless of the conformation of the peptide
tail. We hypothesized the electrostatic charge calcula-
tions were not affected by the conformation of the
peptide tail as all modelled short peptide tails have a
highly similar initial conformation.
Electrostatic calculations were performed with APBS
V1.2.1 and the molecular surfaces with the electrostatic
properties were rendered with both VMD V1.8.7 and
PyMOL V1.2.
Energy minimizations and molecular dynamics
simulations in a water box
The peptide-NSD-CD complexes were fully solvated in a
water box (140 ? ? 100 ? ? 110 ?) using VMD 1.9. Then H3 and H4 substrates in vitro. HMTase activities of NSD1-CTD,
red using colorimetric quantification (See Materials and Methods). HMTase
duplicate. The error bars indicate standard deviations. The results were
isks indicate P-values; *p < 0.05, **p < 0.02, ***p < 0.005, ****p < 0.001.
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and molecular dynamics (MD) contained the following
number of atoms: NSD1-CD-H3K4(1? 7), 42,121 atoms;
NSD1-CD-H3K9(5? 11), 42,104 atoms; NSD1-CD-H3K27
(23? 27), 42,095 atoms; NSD1-CD-H3K36(32? 38), 42,106
atoms; NSD1-CD-H3K79(75? 81), 42,120 atoms; NSD1-
CD-H4K20(32? 38), 42,130 atoms; NSD2-CD-H3K4(1? 7),
44,848 atoms; NSD2-CD-H3K9(5 ? 11), 44,840 atoms;
NSD2-CD-H3K27(23 ? 27), 44,828 atoms; NSD2-CD-
H3K36(32 ? 38), 44,830 atoms; NSD2-CD-H3K79(75 ?
81), 44,844 atoms; NSD2-CD-H4K20(32 ? 38), 44,860
atoms; NSD3-CD-H3K4(1 ? 7), 44,367 atoms; NSD3-
CD-H3K9(5 ? 11), 44,353 atoms; NSD3-CD-H3K27(23 ?
27), 44,341 atoms; NSD3-CD-H3K36(32 ? 38), 44,349
atoms; NSD3-CD-H3K79(75 ? 81), 44,366 atoms; NSD3-
CD-H4K20(32 ? 38), 44,379 atoms. About 90 % of the
atoms were from the water molecules. EM and MD
were performed with NAMD v2.8 using the CHARMM
force field. A constant temperature was maintained
using a Langevin damping at 300 K, and the pressure
was held constant at 1 atmosphere with a Langevin
piston. Electrostatic forces were taken into account
using the particle mesh Ewald (PME) method with a 10
? cut-off distance. The solvated complexes, histone-
peptide-NSD-CD, were first equilibrated with 5,000
steps (5 ns) of conjugate gradient EM followed by 5
cycles of 20,000 steps (20 ns) of MD and 5,000 steps (5
ns) of EM. The last step was 5 ns of EM. Each solvated
complex of histone-peptide-NSD-CD was subjected to
a total of 100,000 steps (100 ns) of MD and a total of
30,000 steps (30 ns) of EM. EM steps were long enough
to reach a local minimum with Δε < 1 kJ/mol. After the
MD simulations, the solvated complexes were manually
checked for ideal stereochemistry with COOT. The
MD trajectories were analyzed with VMD 1.9 and the
plots of the total energy versus timescale were plotted
using Gnuplot 4.4.
Binding energy determination
Binding energy was calculated as follows: εbinding = εcom-
plex ? (εpeptide + εNSD) using the total energy calculations
of NAMD [47]. Models of the last MD step were
stripped from solvent molecules and used to calculate
the binding energy of the complex. Models of the bind-
ing complex, peptides, and NSD-CD apo were all
subjected to the same EM procedure prior to binding
energy calculation. Models were energy minimized with
4,000 steps (4 ns) of conjugate gradient EM followed by
2,000 steps (2 ns) of MD and 6,000 steps (6 ns) of EM
(NAMD v2.8) [47]. EM steps were long enough to
reach a local minimum with Δε < 1 kJ/mol. A constant
temperature was maintained by using Langevin damp-
ing at 300 K and the pressure was held constant at 1
atmosphere with a Langevin piston.Model analysis and validation
The details of the interactions between the NSD-CD and
H3- or H4- peptides were analyzed with Ligplot [48]. The
confirmation of interaction maps was manually done
through visual inspections of the models in COOT [49].Results
The CTD of NSD members can methylate multiple histone
lysines in vitro
To examine whether the CTD of NSD1, NSD2, and
NSD3 specifically recognizes and methylates multiple
lysines of H3 and H4 in vitro, we quantified the pan-
methylation of NSD1-CTD, NSD2-CTD, and NSD3-
CTD on H3K4, H3K9, H3K27, H3K36, H3K79, and
H4K20 (Figure 2).
Reinberg and colleagues reported that NSD2-SET
domain methylates H4K44 on octamers, which could be
linked to histone deposition and/or to the response to
DNA damage [36]. Although H4K44 methylation re-
mains to be investigated, it was omitted in this study
due to lack of a suitable and consistent assay.
Overall, NSD1-CTD, NSD2-CTD, and NSD3-CTD ex-
hibit similar substrate recognition and methylation prop-
erties, but reduced methylation activities were observed
for NSD3-CTD (Figure 2). H3K4me3 and H3K27me3 spe-
cies were preferably detected rather than ? me1 and ? me2
species for both NSD1-CTD and NSD2-CTD. In contrast,
H3K9-me1 & -me2 and H3K79-me1 & -me2 species were
favored against ? me3 species.
Unlike NSD1-CTD and NSD2-CTD, NSD3-CTD
showed a lower, but significant, activity (up to ~1.5 fold
increase in methylation fold for almost all substrates
tested, except for the marginal activity on H3K4 and
H3K9) and the methylation properties of NSD3-CTD on
H3K9, H3K27, and H3K79 were almost identical to those
of NSD1-CTD and NSD2-CTD. However, H4K20 methy-
lation varied among all NSD-CTDs. Nonetheless, signifi-
cant activity of NSD1-CTD on mono-/tri-methylation,
NSD2-CTD on di-/tri-methylation, and NSD3-CTD on
di-/tri-methylation of H4K20 were observed, indicating
that H4K20 is an in vitro target for all NSD-CTDs. Im-
portantly, H3K36 was methylated by all NSD-CTDs and
appears to be the preferable in vitro substrate for NSD1-
CTD.
Taken together, our data indicate that, in vitro, the
CTD of NSD1, NSD2, and NSD3 is able to recognize
and methylate H3K4, H3K9, H3K27, H3K36, H3K79,
and H4K20 with significant differences in catalytic
activities depending on the substrate. Although some
HMTases (such as SET9) do not retain significant meth-
yltransferase activity in vitro [50], this was not the case
for NSD members, where significant enzymatic activities
were measured (Figure 2).
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conformation of the catalytic domain
Our data showed that, in vitro, the CTD of NSD1, NSD2,
and NSD3 has the ability to recognize and methylate
several histone lysines (Figure 2). To gain further insight
into histone lysine methylation by the NSD members, we
investigated conformational modifications of the catalytic
domain (CD) to gain access to the lysine-binding pocket.
The crystal structure of NSD1-CD (PDB: 3OOI) is devoid
of substrate and the histone-lysine binding area is oc-
cluded by a regulatory loop at the interface of the SET and
post-SET regions (Figure 3) [9,51]. Previously, we showed
that molecular determinants of this regulatory loop extend
over the histone-binding site, sterically preventing sub-
strates from binding [51-53]. The H3K4 HMTase MLL1
also has been described to have a flexible post-SET
responsible for the open-and-closed conformation of the
lysine-substrate binding site [53].Figure 3 The opening motion of the catalytic domain. Left panel: The
β-sheets arranged in a triangular fashion with a group of two β-sheets clos
of the lysine-histone ligand. The cofactor SAM binds in a cavity adjacent to
shown in red. The motion of the regulatory loop is indicated with bent bla
H3-peptide (a.a. 32? 38) after MD simulations. H3K36 is indicated by an arro
red: negative charges with unit +5/-5 kb.T.ec
−1.The crystal structure of NSD1-CD (PDB: 3OOI - a.a.
1850 ? 2080) was used to build the corresponding CDs of
NSD2 and NSD3 by homology modelling. A pair-wise
sequence alignment between the template and the target
showed that the NSD2-CD (a.a. 971? 1202) shares 75.9 %
identity and 90.1 % similarity with the NSD1-CD (PDB:
3OO1), whereas the NSD3-CD (a.a. 1044? 1283) shares
72.9 % identity and 85 % similarity with the NSD1-CD.
Protein sequences sharing at least 40 % identity are likely
to share similar structures, thus all NSD1-CD, NSD2-CD,
and NSD3-CD are likely to share a similar scaffold
(Figure 1).
Next, we used molecular dynamics (MD) to investigate
the docking of peptides containing histone lysine (H3K4,
H3K9, H3K27, H3K36, H3K79, and H4K20), NSD1-CD,
NSD2-CD, and NSD3-CD. The initial models were
based on the crystal structure of NSD1-CD solved in a
closed apo-conformation. Therefore, models of the apostructure of the CD is composed of three groups of canonical
ely neighbouring a conserved α-helix defining a cleft for the binding
the CD connected through a channel. The flexible regulatory loop is
ck closed arrows. Right panel: Model of the NSD-CDs bound with the
w. The electrostatic surface is colored as follows: blue: positive charges;
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were deliberately brought into a sterically unstable
conformation. Energy minimizations and long MD
simulations performed in a water box centered on the
protein relieved the steric clashes and forced the CDs
into an open conformation that accommodates substrates
(Figures 3, 4, 5 and Additional file 1: Figure S1). Long-
range MD simulations were applied to allow complexes to
equilibrate into stable conformations with little RMSD
oscillations observed for the post-SET regions (overall cα-
RMSD < 0.6 ?) [9]. The resulting models may approximateFigure 4 Molecular determinants of the binding of H3K4, H3K9 and H
(a.a. 23? 29) are oriented vertically and depicted in purple with the atomic det
NSD members are indicated in brown and numbered. Green dashed lines rep
declutter the figure. The schematic was generated with the program Ligplot.the conformations of the opened CD potentially resulting
from the binding of nucleosomal DNA as an allosteric ef-
fector. Following the MD simulations, the structural modi-
fications observed were on the CD of NSD2 and NSD3,
specifically on a loop at the interface between the SET and
post-SET regions (a.a. 1178 to 1191 for NSD2-CD and a.a.
1260? 1273 for NSD3-CD). This specific loop rotated ~40?
and translated ~6 ? at the tip, which is a significant
displacement (Figure 3) [9]. The rest of the backbone did
not undergo significant structural modifications, with an
overall cα-RMSD < 0.6 ?.3K27. The peptides H3K4 (a.a. 1-7), H3K9 (a.a. 5? 11), and H3K27
ails of the side chains. The interacting amino acids from the CDs of the
resent the hydrogen bonds. The hydrophobic interactions are omitted to
Figure 5 Molecular determinants of the binding of H3K36, H3K79 and H4K20. The peptides H3K36 (a.a. 32? 38), H3K79 (a.a. 75? 81),
and H4K20 (a.a. 16-22) are shown. Details are the same as in Figure 4.
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H3K79, and H4K20 peptides
The CDs of the NSDs are likely to share highly similar
structural features (Figure 3). The histone tail-binding area
only becomes accessible when the regulatory loop at the
interface between the SET and post-SET regions is rotated
and displaced, exposing a negatively-charged surface area
suitable for the docking of the positively charged H3 and
H4 peptide tails (Figure 3).
As a step forward towards understanding the molecu-
lar details of substrate recognition by NSD-CDs, we used
MD simulations to examine the binding characteristics
of H3K4, H3K9, H3K27, H3K36, H3K79, and H4K20peptides. Overall, our data indicate that all the histone
H3 and H4 peptides tested (H3K4 a.a. 1-7; H3K9 a.a.
5-11; H3K27 a.a. 23-29; H3K36 a.a. 32-38; H3K79 a.a.
75-81; H4K20 a.a. 16-22) share similar steric hindrance
and have similar positive charges related to their electric
field and molecular surface. These properties imply
favourable binding energies for the NSD-CDs (Table 1).
The total energy of the complexes after the MD simula-
tions was highly comparable between the tested substrates
(standard deviation of 0.12 % for both NSD1 and NSD2,
and 0.11 % for NSD3), indicating that all peptides tested
similarly bind to the NSD members (Table 1). In addition,
the regulatory loop acts as a ? seat belt? to anchor a single
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lysine substrate to extend toward the cofactor-binding site
for the catalytic reaction to occur (Figure 3). The peptide-
binding area is large enough to accommodate a seven-
amino acid peptide. Interestingly, the seven-a.a. peptides
(containing H3K4, H3K9, H3K27, H3K36, H3K79, and
H4K20) share highly similar steric and electrostatic prop-
erties (Figures 3, 4 and 5). In addition, all the H3 and H4
histone peptides tested were also firmly stabilized into the
histone-tail binding cleft of NSD1, NSD2, and NSD3 by
an extensive network of hydrogen bonds (Figures 4 and 5).
This observation is consistent with the calculated binding
energies, reflecting the proper steric and electrostatic
compatibilities between histone peptides and the CDs
(Table 1).
The binding of histone H3 and H4 peptides induces
significant modifications to the histone-binding pocket.
In addition to the movement of the regulatory loop seat-
ing on top of the histone tail, an induce-fit mechanism
triggers changes locally in the backbone along with the
rotation of the side chain of key amino acids creating an
extensive network of hydrogen bonds anchoring the H3
and H4 peptides (Figures 4 and 5). Specifically, H3K4 (a.a.
1-7) peptide is stabilized by hydrogen bonds with Ala1989,
Asp1993, Thr1995, Asn1996, Phe1997, Met2020, Arg2018,
Tyr2059, Leu2064 and Asn2066 in NSD1, with Tyr1091,
Ala1108, Asn1111, His1115, Met1118, Ser1136, Asn1140,
Tyr1178 and Asn1185 in NSD2, and with Tyr1173,
Ala1190, Val1195, Thr1196, Asn1197, Phe1198, Met1200,
Ser1218, Met1221, and His1273 In NSD3. H3K9 (a.a. 5-11)
peptide is stabilized by hydrogen bonds with Phe1997,
Thr2001, Arg2018, Met2020, Met1999, Tyr2059, Glu2062,
Cys2063, Leu2064 and Asn2066 in NSD1, with Asp1112,
Met1118, Thr1120, Arg1137, Met1139, Leu1183 and
Asn1185 in NSD2, and with Met1200, Met1221, Asn1267,
Asn1197, Phe1198, and Thr1270 in NSD3. H3K27 (a.a. 23-
29) peptide is stabilized by hydrogen bonds with Thr1995,
Phe1997, Met1999, Arg2018, Met2020, Asn2021, Cys2063,Table 1 Binding energy of peptides containing lysine-
histone substrates onto the CD of NSD1, NSD2, and NSD3
(kcal/mol) NSD1 NSD2 NSD3
H3K4 −229.7 −299.4 −200.5
H3K9 −353.2 −280.4 −282.9
H3K27 −151.9 −252.6 −247.4
H3K36 −277.1 −272.2 −261.6
H3K79 −285.6 −332.4 −254.3
H4K20 −277.2 −269.5 −289.0
polyE 444.2 862.9 663.2
Peptides are as follows: H3K4 (a.a. 1? 7); H3K9 (a.a. 5 ? 11); H3K27 (a.a. 23 ? 29);
H3K36 (a.a. 32 ? 38); H3K79 (a.a. 75 ? 81); H4K20 (a.a. 16 ? 22). The polyE is a
6-mer poly-glutamic acid peptide used as a control experiment for the
docking studies.Asn2066 and Thr2069 in NSD1, with Tyr1091, Asp1112,
Thr1114, Phe1116, Thr1120, Arg1137, Met1139, Tyr1178,
Asp1181, Leu1183, Asn1185 and Thr1188 in NSD2, and,
with Thr1196, Phe1198, Met1200, Arg1219, Met1221,
Asp1263, Cys1264, Leu1265, Asn1267, Arg1269 and
Thr1270 in NSD3. H3K36 (a.a. 32-38) peptide is stabilized
by hydrogen bonds with Asp1193, Phe1997, Met1999,
Arg2018, Met2020, Asn2021, Glu2062 and Asn2066 in
NSD1, with Thr1114, Phe1116, Arg1137, Met1139,
Leu1180, Cys1182, Gly1184, Asn1185 and Glu1186 in
NSD2, and, with Thr1270, Thr1196, Phe1198, Met1200,
Arg1219, Met1221, Asp1263 and Cys1264 in NSD3.
H3K79 (a.a. 75-81) peptide is stabilized by hydrogen bonds
with Ile1994, Phe1997, Arg2018, Met2020, Thr2030,
Lys2032, Cys2063, Asn2960, Asn2066 and Thr2069 in
NSD1, with Trp1074, Ala1108, His1109, Ile1113, Thr1114,
His1115, Phe1116, Phe1138, Met1139, Asn1140, Thr1149,
Asn1179, Leu1180, Leu1183, Asn1185, and Arg1191 in
NSD2, and with Asn1197, Phe1198, Met1200, Arg1219,
Met1221, Thr1231, Lys1233, Tyr1260, Cys1264, Asn1267
and Thr1270 in NSD3. H4K20 (a.a. 16-22) peptide is stabi-
lized by hydrogen bonds with Trp1955, Ile1994, Thr1995,
Phe1997, Arg2018, Met2020, Tyr2059, Leu2061, Glu2062,
Cys2063, Asn2066 and Thr2069 in NSD1, with Ala1108,
Asn1111, Ile1113, Thr1114, Phe1116, Met1118, Arg1137,
Met1139, Asn1140, Tyr1178, Asp1181, Cys1182, Asn1185
and Thr1188 in NSD2, and with Val1195, Thr1196,
Asn1197, Phe1198, Arg1219, Met1221, Asn1222, Tyr1260,
Asp1263, Asn1267 and Thr1270 in NSD3.
The docking of all histone peptides on the CD is asso-
ciated with a significantly favorable docking energy,
highlighting good substrate compatibilities. As a control
experiment, we modelled the docking of a largely elec-
tronegative 7-mer poly-glutamic acid (polyE) peptide
that induces significant steric hindrance in the peptide
binding-pocket. The docking of the polyE peptide is
associated with highly unfavorable binding energies,
highlighting its poor fit to any of the NSD-CDs, as antic-
ipated (Table 1).
Taken together, our data indicate that the histone-
binding pocket of the NSD members is equally compat-
ible with the histone peptides tested, offering steric and
electrostatic matches for the stabilization of the H3 and/
or H4 histone tail(s).Discussion
HMTases are essential in maintaining chromatin through
modifications of histone tails. In this study, we examined
the histone-lysine recognition and methylation properties
of NSD1-CTD, NSD2-CTD, and NSD3-CTD in vitro to
understand the extent of their catalytic properties and
provide medicinal chemistry insights into the design of
NSD inhibitors.
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methyltransferase activity in vitro [50], unlike CTDs of
NSD1, NSD2, and NSD3 (Figure 2). Although significant
differences in methyltransferase activities have been ob-
served, it is unambiguous that the CTD can recognize and
methylate various histone substrates in vitro (Figure 2).
Our data indicate that the CTDs of NSD1, NSD2, and
NSD3 recognize and methylate H3K4, H3K9, H3K27,
H3K36, H3K79 and H4K20 in vitro (Figure 2). In addition,
other work has shown H4K44 methylation by the NSD2-
SET domain on octamers [36]. This contrasts with in vivo
results where the NSDs are exclusive to one substrate
H3K36 or H4K20.
In vivo, NSD2 activity is specific to either H3K36 or
H4K20 depending on the cellular context [17,20]. The
level of HMTase activity also depends on the nature of
the substrate (peptide, histone, or nucleosome). The
NSD2 SET domain alone can also methylate H3K36
in vitro, generating at least H3K36me1 [36]. H3K36
methylations have been predominantly reported for the
NSD members and have significant roles in transcrip-
tional activation, alternative splicing events, and DNA
repair [24,54-56]. Methylations on H3K4, H3K9, H3K27,
H3K79, and H4K20 by NSD members have also been
identified. NSD members might possibly have unique
methylation capabilities that respond to a specific cellu-
lar context in vivo.
The methylation of non-histone protein targets has
previously been shown for HMTases such as G9a targets,
WIZ, CDYL1, and ACINUS [57], and SET7/9 target,
SUV39H1 [56]. G9a is capable of automethylation on the
non-enzymatic N-terminal part of the enzyme [57]. Inter-
estingly, NSD1 and NSD2 methylate both histone and
non-histone substrates equally. NF-κB is activated through
NSD1-mediated mono- and di-methylation on lysine 218
[42]. NSD2 directly interacts with NF-κB for the activation
of target genes, including IL-6, IL-8, VEGFA, cyclin D,
Bcl-2, and survivin in castration-resistant prostate cancer
cells (CRPC) [4]. NSD2 is recruited to the target gene pro-
moters upon induction and mediates NF-κB activation-
associated elevation of histone H3K36me2 and -me3
marks at promoters [8,42]. Less is known about NSD3,
but non-histone methylation is potentially one of its bio-
logical functions as well.
In the absence of substrate, the histone-binding pocket
of the NSD members is closed, similar to the H3K9
HMTase MLL1 [53]. Our data suggest that the binding
of the histone-peptide itself is not entirely responsible
for displacing the post-SET regulatory loop in vivo.
Instead, the binding of histones or nucleosomal DNA
could be an allosteric effector that triggers the opening
of the catalytic domain. Nonetheless, our assays indicate
that, in vitro, the binding of either H3 or H4 histone
triggers the opening of NSD-CD. The binding cavityappears to equally accommodate the 7-mer histone pep-
tides tested (H3K4 a.a. 1-7; H3K9 a.a. 5-11; H3K27 a.a. 23-
29; H3K36 a.a. 32-38; H3K79 a.a. 75-81; H4K20 a.a. 16-22),
likely due to all being electrostatically positively charged
and presenting homologous steric hindrance. In the case of
NSD2, the binding of the H4K20 peptide is favorable and
stabilized by an extensive network of hydrogen bonds. The
binding of the H3K36 peptide is strongly anchored in the
opened-SET domain of NSD2 with ten hydrogen bonds
(thirteen for H4K20 a.a. 16-22) (Figure 5). However, a bet-
ter catalytic efficiency in vitro is observed on H3K36 rather
than H4K20, which could perhaps be ascribed to a more
favorable conformation of the lysine substrate (Figure 2).
Differences calculated in binding energies can be due to
differential stabilization properties, which are not necessar-
ily linked with catalytic efficiencies.
Analysis of peptide-protein interactions reveals a con-
served binding motif for all the NSD members composed
of a quartet of Phenylalanine, Arginine, Methionine and
Asparagine (Figures 4 and 5). The trio of conserved
Phenylalanine, Arginine and Methionine is located on the
pre-SET domain Phe1197 (NSD1), Phe1116 (NSD2),
Phe1198 (NSD3); Arg2018 (NSD1), Arg1137 (NSD2),
Arg1219 (NSD3); Met2020 (NSD1), Met1139 (NSD2),
Met1221 (NSD3) whereas the Asparagine consensus
Asn2066 (NSD1), Asn1185 (NSD2) and Asn1267 (NSD3)
sits at the interface of the SET and post-SET region, on
the flexible regulatory loop we previously identified [9]. In
addition, a specific conserved binding motif can be identi-
fied for only a pair of NSDs: Met1999 (NSD1) and
Met1200 (NSD3); Tyr2059 (NSD1) and Tyr1178 (NSD2);
Thr114 (NSD2) and Thr1196 (NSD3). Moreover, peptide-
protein interaction specific for each NSD completes the
binding motif with Cys2063 (NSD1 specific), Asn1140
(NSD2 specific), Asn1197 & Asp1263 & Thr1270 (NSD3
specific). Taken together, the differences observed within
the binding motifs amongst the NSDs offer possibilities of
discrimination that may be exploited in a drug design
strategy targeting the histone tail-binding site.
The post-SET regulatory loop sits on top of the histone-
peptide, stabilizing the complex and forcing the lysine sub-
strate into the catalytic channel extending deep toward
the co-factor-binding site. In all cases, the lysine substrate
extends into the narrow channel connecting the co-factor-
binding site in order to react and is anchored by two
hydrogen bonds, except for NSD3 with H3K4 and H3K9
where the lysine substrate is bonded by a single hydrogen
bond. This double-hydrogen bond is found in other
lysine-HMTases and appears to be associated with cata-
lytic efficiency. This observation is consistent with the
peptide-bound structures of H3K9-HMTases (GLP and
Dim-5) where the Lys9 is stabilized by a pair of analogous
hydrogen bonds [52]. A similar conserved double-
hydrogen bond is observed in the structures of H4K20-
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NSD2, the H3K36 lysine is anchored by two hydrogen
bonds whereas the H4K20 lysine is strongly held in
place by three hydrogen bonds. In addition, the H3K36
a.a. 32-38 peptide is stabilized by a network of ten
hydrogen bonds compared to thirteen for the H4K20 a.
a. 16-22 peptide (Figure 5). This observation is consist-
ent with a more favorable binding energy of H4K20 a.a.
16-22 compared to the H3K36 a.a. 32-38 peptide
(Table 1). Our data indicate that NSD3-CTD has com-
parably poor HMTase activities on H3K4 and H3K9,
which appear to be correlated with the Lys4 and Lys9
being anchored by only one hydrogen bond. Overall,
the stabilization of the lysine substrate is established by
a pair of hydrogen bonds that tightly anchor the lysine
substrate in the narrow catalytic channel, affecting
catalytic efficiency (Figures 2, 3, 4 and 5).Conclusions
Our data suggest that the NSD members may not be ex-
clusive to a single histone mark in vivo. We show that the
CTDs of NSD members can carry out pan-methylation of
lysine substrates and generate K-me1, K-me2, and K-me3
species in vitro. However, in vivo cell-based assays have
predominantly identified K-me2 or K-me3 species depend-
ing on the cellular context [2,13,17,18]. Our molecular
modelling data indicate that the binding-groove can
equally accommodate K-me2 or K-me3 species. This is
consistent with a regulatory mechanism distinct from the
CD and carried out by the PHD4 domain to control the
localization and the degree of methylation by NSD mem-
bers [46]. Interestingly, the PWWP domain of the fission
yeast Set9 partner, Pdp1, controls Set9-mediated H4K20
methylation and appears to directly interact with histones
for Set9 localization [50]. Moreover, the sequence conser-
vation is high between Pdp1-PWWP and both PWWP do-
mains of NSD1, NSD2, and NSD3 [50]. The hydrophobic
residues in Pdp1-PWWP responsible for the recognition
of H4K20 marks are also conserved in the two NSD-
PWWP domains [50]. Like Pdp1, the NSD members may
localize to chromatin through the assistance of PWWP
domains. Further analysis to elucidate the role of the
PWWP domains in the NSD members will greatly
improve our understanding of the regulation of histone-
lysine methylations.Additional file
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